Background: The best regimen for the treatment of Helicobacter pylori infection has yet to be defined. Four-day quadruple therapy with tetracycline, metronidazole, bismuth, and a proton pump inhibitor has been shown to obtain a very high cure rate. However, the fact that it must be taken four times daily may interfere with compliance. The objective of the study was to test the efficacy and tolerability of a new 4-day therapy with 4 drugs taken every 12 hours to cure H. pylori infection. Patients and Methods. Fifty-six consecutive patients with peptic ulcer disease and H. pylori infection were treated with an oral 4-day course with omeprazole (20 mg/12 hours), clarithromycin (500 mg/12 hours), amoxicillin (1 g/12 hours) and tinidazole (500 mg/12 hours). Efficacy of the treatment was determined at least 2 months after therapy either by biopsy (in the case of gastric ulcer) or by 13C-urea breath test. A second breath test was performed at least 6 months after therapy.
Results: Two patients were lost to follow-up. Forty-nine of the remaining 54 patients were cured at the first control [intention-to-treat cure rate: 87.5% (CI 95% 75-94%); per protocol cure rate: 90.7% (CI 95% 81-98%)]. Forty-three of these 49 cured patients returned for a second 13C urea breath-test at 6-12 months. Two of them were not cured, giving a long-term cure rate of 85.5% per protocol and 73.2% by intention-to-treat. Compliance was good, although 25 patients had mild side effects.
Conclusion: This particular four-day therapy is well tolerated, easy to follow, and achieves an acceptably high cure rate.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1046/j.1523-5378.2000.00007.x | DOI Listing |
Radiat Oncol
January 2025
Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan.
Introduction: Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases is potentially curable by radical treatment. This study aimed to evaluate the efficacy and safety of chemoradiotherapy (CRT) for thoracic disease, including the primary lesion and lymph node metastases, combined with local consolidative therapy (LCT) for oligometastases.
Methods: This was a multicenter Phase II trial for patients with Stage IV NSCLC with oligometastases for whom CRT for thoracic disease was feasible.
Transplant Cell Ther
January 2025
University of Kansas Medical Center, Kansas City, KS.
Background: Allogeneic hematopoietic cell transplantation (allo-HCT) is a potential cure for many hematological malignancies. Historically, older adults were not considered eligible for allo-HCT due to increased toxicity and mortality concerns. This systematic review and meta-analysis aim to explore the outcomes of allo-HCT in patients aged 70 years or older.
View Article and Find Full Text PDFInt J Gynaecol Obstet
January 2025
Postgraduate Program in Medicine, Surgical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Objective: This paper evaluates the accuracy of C-reactive protein (CRP), leukocyte count, and neutrophil-to-lymphocyte ratio (NLR) for diagnosing tubo-ovarian abscess (TOA) and assessing the cost-effectiveness of different treatment regimens for pelvic inflammatory disease (PID), with and without TOA.
Method: A retrospective cohort study was conducted between January 1, 2003, and December 30, 2021, including women aged 13-80 years diagnosed with PID. The analysis focused on the incremental cost-effectiveness ratio of different treatment regimens.
Front Pharmacol
December 2024
Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia.
Front Neurol
December 2024
Rehabilitation Department, The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
Objective: This study aimed to systematically evaluate the clinical efficacy of Jingjin (muscle region of the meridian, sinew/tendon/fascia) acupuncture therapy in treating peripheral facial paralysis.
Methods: A computerized search of PubMed, EMBASE, Cochrane Central Register of Controlled Clinical Studies, SCOPUS, Web of Science, PEDro, China Knowledge, Wanfang, and Wipu databases was performed for published randomized controlled trials (RCTs) on the treatment of peripheral facial paralysis using Jingjin acupuncture therapy from the beginning of the construction of the databases until 2 April 2024. After a two-person independent extraction of data, the studies were assessed for paper quality and then analyzed for meta-analysis using RevMan5.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!